{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020211","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2022-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.175757+00:00","generated_at":"2026-06-23T00:43:37.206438+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lyra Therapeutics restates Q1/Q2 2022 financials due to $5M milestone error","bullets":["Audit Committee concludes Q1 and Q2 2022 financials no longer reliable due to $5.0M milestone revenue recognition error from LianBio agreement.","Restatement will correct the treatment of variable consideration; cash position unchanged.","Material weakness identified in internal controls over accounting for complex, nonrecurring transactions.","Company expects to file restated financials as soon as practicable."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020211","json":"https://secwatch.observer/filing/0000950170-22-020211.json","markdown":"https://secwatch.observer/filing/0000950170-22-020211.md","text":"https://secwatch.observer/filing/0000950170-22-020211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017022020211/0000950170-22-020211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017022020211/lyra-20221026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:43:37.206438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}